ArticleClinical rheumatology2021
Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.
Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Magnetic resonance imaging changes of thigh muscles in dermatomyositis patients with anti-Mi2 antibody.Annals of medicine · 2026Article
- Acute Muscle Injury and Subcutaneous Edema in a Patient with Anti-nuclear Matrix Protein-2 Antibody Positive Dermatomyositis Sine Dermatitis.Internal medicine (Tokyo, Japan) · 2026Article
- Relapse in adult idiopathic inflammatory myopathies: clinical predictors and the potential role of anti-NXP2 in a single-center retrospective cohort study.Clinical rheumatology · 2026Article
- Bladder carcinoma associated with anti-NXP2-positive inflammatory myopathy: a case-based review.Rheumatology international · 2026Review
- Increased severity and relapse rate in adult anti-nuclear matrix protein 2 antibody positive myositis patients with distal limb weakness: a retrospective study in China.Frontiers in medicine · 2026Article
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- Tongue myositis in dermatomyositis with anti-PM-Scl 75 antibody: two case reports.BMC musculoskeletal disorders · 2025Article
- Pseudoangioedema as a presenting symptom of dermatomyositis with antinuclear matrix protein 2 autoantibodies.JAAD case reports · 2025Article
- Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.RMD open · 2024Article
- NXP-2 positive dermatomyositis with marked dysphagia following an insect bite.Clinics (Sao Paulo, Brazil) · 2024Article
- Review
- Dermatomyositis: a debilitating paraneoplastic phenomenon following a diagnosis of localised squamous cell carcinoma of the cervix.BMJ case reports · 2023Article
- Expanding the clinical phenotype of nuclear matrix protein 2 antibody-positive dermatomyositis.JAAD case reports · 2023Article
- Myositis interstitial lung disease and autoantibodies.Frontiers in medicine · 2023Review
- Juvenile dermatomyositis and nephrotic syndrome: A case report and a mini literature review.Frontiers in pediatrics · 2023Article
- Comparison of cytokine/chemokine profiles between dermatomyositis and anti-synthetase syndrome.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesThe aim was to study and compare the clinical manifestations, auxiliary examinations, and therapeutic responses in patients with different myositis-specific antibody (MSA) types.
methodWe retrospectively investigated the medical records of 143 hospitalized dermatomyositis patients, all of whom were tested for MSAs, and performed follow-up. Patients were divided into groups with and without anti-nuclear matrix protein 2 (NXP2) antibodies (17 vs 126 patients). Demographic, clinical manifestation (occurring at any time during the disease course), imaging, laboratory, treatment response, and survival data were collected for statistical analyses.
resultsAdult dermatomyositis patients with anti-NXP2 antibodies were more prone to dysphagia (P<0.001), had higher levels of muscle injury markers (CK peak, P=0.007; CK peak>1000 IU/L, P<0.001; CK-MB, P=0.002), were younger at onset (P=0.008), and were less likely to present with interstitial lung disease (P=0.016) than the anti-NXP2 antibody-negative subgroup. Multivariable logistic regression analysis showed that onset age (OR=0.96 CI 95%: 0.924-0.999, P=0.043) and dysphagia (OR=7.088, CI 95%: 1.824-27.536, P=0.005) were independent risk factors for anti-NXP2 antibody positivity. Kaplan-Meier survival analysis did not reveal that dermatomyositis patients with anti-NXP2 antibodies have a relatively worse prognosis. However, the disease course was more frequently polycyclic, and 68.75% of patients had a relapsing-remitting disease course. More than half (52.94%) of those who showed no response to treatment used at least 3 disease-modifying antirheumatic drugs.
conclusionsWe show the important clinical features of and risk factors for this unique antibody-mediated form of dermatomyositis. Although these patients had a relatively low mortality rate, they were prone to recurrence, and treatment was challenging. Key points • The clinical features and risk factors for adult dermatomyositis patients with anti-NXP2 antibodies. • The impact of anti-NXP2 antibody on survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.